Delaware Healthcare’s attractive, ordinary, and unappealing features continue to offset each other, and it remains a middling source of exposure to its target sector.
Delaware Healthcare C DLHCX
- NAV / 1-Day Return 26.13 / +0.42 %
- Total Assets 825.8 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.960%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 5%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:50 PM GMT+0
Morningstar’s Analysis DLHCX
Will DLHCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 10.13 | 84.5 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 6.67 | 55.7 Mil | Healthcare |
Amgen Inc | 6.40 | 53.4 Mil | Healthcare |
UnitedHealth Group Inc | 5.38 | 44.9 Mil | Healthcare |
Merck & Co Inc | 4.73 | 39.4 Mil | Healthcare |
Elevance Health Inc | 4.20 | 35.1 Mil | Healthcare |
Pfizer Inc | 3.98 | 33.2 Mil | Healthcare |
Boston Scientific Corp | 3.73 | 31.1 Mil | Healthcare |
Roche Holding AG | 3.25 | 27.1 Mil | Healthcare |
AbbVie Inc | 3.06 | 25.5 Mil | Healthcare |